Lifecore Biomedical, Inc. (NASDAQ:LFCR) is Greenhaven Road Investment Management L.P.'s 4th Largest Position

Greenhaven Road Investment Management L.P. increased its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 62.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,616,146 shares of the company's stock after purchasing an additional 1,387,362 shares during the quarter. Lifecore Biomedical makes up approximately 4.3% of Greenhaven Road Investment Management L.P.'s portfolio, making the stock its 4th biggest holding. Greenhaven Road Investment Management L.P. owned 9.77% of Lifecore Biomedical worth $26,868,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of LFCR. Barclays PLC grew its stake in Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company's stock valued at $147,000 after buying an additional 22,489 shares in the last quarter. State Street Corp grew its position in shares of Lifecore Biomedical by 10.2% in the third quarter. State Street Corp now owns 334,360 shares of the company's stock valued at $1,648,000 after purchasing an additional 30,916 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Lifecore Biomedical by 101.7% during the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company's stock valued at $179,000 after purchasing an additional 18,277 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in Lifecore Biomedical by 61.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company's stock worth $202,000 after purchasing an additional 10,320 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company's stock worth $2,948,000 after purchasing an additional 55,703 shares during the period. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Price Performance

Shares of LFCR stock traded up $0.15 on Wednesday, reaching $6.33. The company's stock had a trading volume of 62,767 shares, compared to its average volume of 228,216. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $7.99. The stock's 50 day simple moving average is $6.18 and its 200-day simple moving average is $6.34. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The company has a market capitalization of $234.37 million, a P/E ratio of -11.30 and a beta of 0.80.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The business had revenue of $35.15 million for the quarter, compared to the consensus estimate of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, equities analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Stephens reiterated an "equal weight" rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.